DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Vyleesi (autoinjector) is a drug marketed by Palatin Technologies and is included in one NDA. There are five patents protecting this drug.
This drug has seventy-seven patent family members in twenty-four countries.
The generic ingredient in VYLEESI (AUTOINJECTOR) is bremelanotide acetate. One supplier is listed for this compound. Additional details are available on the bremelanotide acetate profile page.
Vyleesi (autoinjector) will be eligible for patent challenges on June 21, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 21, 2024. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
DrugPatentWatch® Estimated Generic Entry Opportunity Date for VYLEESI (AUTOINJECTOR)
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Country||Patent Number||Estimated Expiration|
|Denmark||2916856||Try Before You Buy|
|European Patent Office||2916856||Try Before You Buy|
|Israel||180419||Try Before You Buy|
|Singapore||11201502949Q||Try Before You Buy|
|Japan||2016503406||Try Before You Buy|
|Hong Kong||1211227||Try Before You Buy|
|Mexico||2015005486||Try Before You Buy|
|>Country||>Patent Number||>Estimated Expiration|